Angiogenesis in vestibular schwannomas: Expression of extracellular matrix factors MMP-2, MMP-9, and TIMP-1

Laryngoscope

Volumn 120, Issue 4, 2010, Pages 657-662

  Møller, Martin Nue ^a   Werther, Kim ^b   Nalla, Amarnadh ^d   Stangerup, Sven Eric ^a,d   Thomsen, Jens ^a   Bøg Hansen, Thorkild C ^c   Nielsen, Hans Jørgen ^d,e   Cayé Thomasen, Per ^a,d  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b ENT Clinic   (Denmark)

^c Faculty of Health Sciences   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Acoustic neuroma; Homogenates; Matrix metalloproteinase 2; Matrix metalloproteinase 9; Receptor; Tissue inhibitors of metalloproteinase 1; Vascular endothelial growth factor

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ACOUSTIC NEURINOMA; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SEX DIFFERENCE; SURGICAL APPROACH; SYMPTOM; TISSUE HOMOGENATE; TISSUE LEVEL; TRANSLABYRINTHINE RESECTION; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; VESTIBULAR SCHWANNOMA;

ADULT; AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; NEUROMA, ACOUSTIC; PROSPECTIVE STUDIES; RNA, NEOPLASM; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 77950802772     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.20834     Document Type: Article

References (22)

1. Marti HH. Vascular endothelial growth factor. Adv Exp Med Biol 2002;513:375-394.
2. Zachary I. Vascular endothelial growth factor and antiangiogenic peptides as therapeutic and investigational molecules. IDrugs 2003;6:224-231. (Pubitemid 36717189)
3. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676. (Pubitemid 36749215)
4. Caye-Thomasen P, Baandrup L, Jacobsen GK, Thomsen J, Stangerup SE. Immunohistochemical demonstration of VEGF in vestibular schwannomas correlates to tumor growth rate. Laryngoscope 2003;113:2129-2134.
5. Caye-Thomasen P, Werther K, Nalla A, et al. VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol Neurotol 2005;26:98-101. (Pubitemid 40130217)
6. Koutsimpelas D, Stripf T, Heinrich UR, Mann WJ, Brieger J. Expression of vascular endothelial growth factor and basic fibroblast growth factor in sporadic vestibular schwannomas correlates to growth characteristics. Otol Neurotol 2007;28:1094-1099. (Pubitemid 350191085)
7. Uesaka T, Shono T, Suzuki SO, et al. Expression of VEGF and its receptor genes in intracranial schwannomas. J Neurooncol 2007;83:259-266. (Pubitemid 46952236)
8. Plotkin SR, Stemmer-Rachamimov AO, Barker FG II, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009;361: 358-367.
9. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005;9:267-285.
10. Lakka SS, Gondi CS, Rao JS. Proteases and glioma angiogenesis. Brain Pathol 2005;15:327-341.
11. Munaut C, Noel A, Hougrand O, Foidart JM, Boniver J, Deprez M. Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas. Int J Cancer 2003;106:848-855. (Pubitemid 37071662)
12. Stetler-Stevenson WG, Yu AE. Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol 2001;11:143-152.
13. Moller Sorensen N, Vejgaard Sorensen I, Ornbjerg Wurtz S, et al. Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment. Scand J Gastroenterol 2008;43:774-786.
14. Lomholt AF, Frederiksen CB, Christensen LJ, et al. Plasma tissue inhibitor of metalloproteinases-1 as a biological marker? Pre-analytical considerations. Clin Chim Acta 2007;380:128-132.
15. Frederiksen CB, Lomholt AF, Lottenburg T, et al. Assessment of the biological variation of plasma tissue inhibitor of metallopreteinases- 1. Int J Biol Markers 2008;23:42-47.
16. Cooksley S, Hipkiss JB, Tickle SP, et al. Immunoassays for the detection of human collagenase, stromolysin, tissue inhibitor of metalloproteinases (TIMP) and enzyme-inhibitor complexes. Matrix 1990;10:285-291. (Pubitemid 20358884)
17. Holten-Andersen MN, Murphy G, Nielsen HJ, et al. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 1999;80: 495-503. (Pubitemid 29213206)
18. Van Hinsbergh VW, Koolwijk P. Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc Res 2008;78:203-212. (Pubitemid 351556093)
19. Yang L, Zeng W, Li D, Zhou R: Inhibition of cell proliferation, migration and invasion by DNAzyme targeting MMP-9 in A549 cells. Oncol Rep 2009;22:121-126.
20. Moon KS, Jung S, Seo SK, et al. Cystic vestibular schwannomas: a possible role of matrix metalloproteinase-2 in cyst development and unfavorable surgical outcome. J Neurosurg 2007;106:866-871. (Pubitemid 46698673)
21. Lim M, Guccione S, Haddix T, et al. alpha(v)beta(3) Integrin in central nervous system tumors. Hum Pathol 2005; 36:665-669.
22. Lehmann HC, Kohne A, Bernal F, et al. Matrix metalloproteinase- 2 is involved in myelination of dorsal root ganglia neurons. Glia 2009;57:479-489.